{"filing":{"accession_number":"0001628280-26-055697","cik":"0001077183","ticker":"NEO","company_name":"NEOGENOMICS INC","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-07","primary_document":"neo-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1077183/000162828026055697/neo-20260807.htm"},"events":[{"id":26941,"run_id":24505,"accession_number":"0001628280-26-055697","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Alicia Olivo, EVP and General Counsel, is departing her role effective September 21, 2026, with a transition period through October 2, 2026. The disclosure centers on her departure and associated separation payments under her employment agreement. This is a material executive departure affecting the company's leadership structure.","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28245,"accession_number":"0001628280-26-055697","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Alicia Olivo, EVP and General Counsel, is departing her role effective September 21, 2026, with a transition period through October 2, 2026. The disclosure centers on her departure and associated separation payments under her employment agreement. This is a material executive departure affecting the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:50.945881+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28245,"accession_number":"0001628280-26-055697","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Alicia Olivo, EVP and General Counsel, is departing her role effective September 21, 2026, with a transition period through October 2, 2026. The disclosure centers on her departure and associated separation payments under her employment agreement. This is a material executive departure affecting the company's leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T02:16:50.945881+00:00","company_name":"NEOGENOMICS INC","ticker":"NEO","filing_date":"2026-08-11"}]}